Halozyme - Bathi operasional EBITDA HALO
Risks associated with dependence on a narrow circle of partners and patents are evident in the trend of total EBITDA, where the metric stands at 1160.67. Halozyme Therapeutics (HALO) revenues are based on a unique drug delivery method that generates multi-year passive income. High R&D costs and regulatory barriers create a robust moat for the business against new market entrants.
Halozyme Therapeutics, Inc. (HALO) - rincian metrik lan laporan keuangan
- kuotasi saiki lan rata-rata prakiraan nilai:
- rincian nilai pasar emiten:
- indikator nilai buku ekuitas:
- data tingkat utang lan likuiditas finansial:
Rasio Kabeh Utang marang Dana Pribadi Halozyme Therapeutics|HALO - Utang jangka dawa marang modal|Utang jangka cendhak marang modal Halozyme Corp|HALO - Utang perusahaan|Rasio utang marang kapitalisasi buku Halozyme Therapeutics|HALO - Utang jangka dawa perusahaan|Utang jangka cendhak Halozyme|Rasio likuiditas kritis halozyme.com
- statistik bathi lan rasio pasar:
HALO - Penghasilan resik|Bathi resik sing dikarepake Halozyme Therapeutics|HALO - Rasio rega marang bathi|Prakiraan rega marang bathi Halozyme|HALO - Pangali PEG|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Halozyme Inc.|HALO - Bathi operasional sadurunge ngurangi amortisasi|Bathi saben saham sajroning taun lumaku Halozyme|HALO - Bathi resik saben saham sajrone 12 wulan pungkasan|Kacepetan wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan halozyme.com|HALO - Wutah bathi ing taun lumaku|Dinamika bathi saben saham sing diarepake ing taun ngarep Halozyme Therapeutics
- indikator pendapatan dodolan lan penghasilan bisnis:
Analisis kabeh metrik perusahaan:halozyme.com (HALO)
This indicator measures the amount of cash generated by the core business before deducting interest and amortization. Rising values demonstrate the company's ability to service debt and fund expansion. By analyzing the company's operating result before depreciation and amortization, an investor assesses the real efficiency of operational activities. This trend directly depends on the scaling of licensing payments. For Halozyme Therapeutics (HALO), this reflects the monetization of the ENHANZE platform through royalties.
Pesaing Halozyme Therapeutics (HALO)
Bathi operasional EBITDA beigene.com ONC|RVMD: Bathi operasional sadurunge ngurangi amortisasi|AAPG - Bathi operasional EBITDA|CG Oncology Corp (CGON) - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|UroGen - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|BCAX (Bicara Therapeutics Inc) - Bathi operasional EBITDA|Bathi sadurunge bunga, pajak, lan amortisasi personalis.com PSNL|Bathi operasional EBITDA ERAS|Delcath Systems - Bathi operasional sadurunge amortisasi|Y-mAbs Therapeutics Inc - Bathi operasional sadurunge ngurangi amortisasi|Bathi operasional EBITDA Aura Corp AURA|CADL - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Accuray (ARAY) - Bathi operasional sadurunge ngurangi amortisasi|SLS: Bathi operasional EBITDA|Actuate Therapeutics (ACTU) - Bathi operasional EBITDA|Bathi operasional sadurunge ngurangi amortisasi CTOR|HURA: Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi sadurunge mbayar bunga, pajak, lan amortisasi Protara Therapeutics (TARA)|Bathi perusahaan sadurunge pajak, bunga, lan amortisasi FATE|Bathi operasional EBITDA WHWK (aadibio.com)|Bathi perusahaan sadurunge pajak, bunga, lan amortisasi TCRX (TScan)|CSBR - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi XBIT (XBiotech Inc)|cel-sci.com (CVM) - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi sadurunge ngurangi bunga, pajak, penyusutan, lan amortisasi OSTX (OS Therapies Incorporated)|Bathi sadurunge mbayar bunga, pajak, lan amortisasi Radiopharm Theranostics Ltd|Bathi sadurunge bunga, pajak, lan amortisasi Artiva Biotherapeutics ARTV|Bathi operasional EBITDA ANL|VERU - Bathi sadurunge bunga, pajak, lan amortisasi|Bathi sadurunge mbayar bunga, pajak, lan amortisasi Tempest Therapeutics TPST|xiliotx.com (XLO) - Bathi sadurunge bunga, pajak, lan amortisasi|RENB: Bathi operasional sadurunge ngurangi amortisasi|Bathi operasional sadurunge potongan amortisasi Mural Oncology PLC (MURA)|KAPA (Kairos Pharma Inc) - Bathi operasional sadurunge ngurangi amortisasi|Bathi sadurunge bunga, pajak, lan amortisasi OnKure Therapeutics Inc (OKUR)|GDTC (CytoMed Therapeutics Ltd) - Bathi operasional EBITDA|Bathi operasional sadurunge ngurangi amortisasi Curis, Inc. (CRIS)|Bathi operasional EBITDA APLM|Bathi perusahaan sadurunge pajak, bunga, lan amortisasi THAR|Bathi operasional EBITDA ADVB (advanbiomed.com)|GNPX - Bathi operasional sadurunge ngurangi amortisasi|CLDI: Bathi operasional sadurunge ngurangi amortisasi|SBFM - Bathi operasional EBITDA|Xenetic Biosciences (XBIO) - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|SLRX: Bathi perusahaan sadurunge pajak, bunga, lan amortisasi|PPBT (Purple Biotech Ltd) - Bathi operasional EBITDA|Bathi sadurunge bunga, pajak, lan amortisasi American Oncology Network, Inc. AONC|Bathi operasional EBITDA BGNE|Pendapatan operasional sadurunge ngurangi amortisasi Checkpoint Therapeutics|Elevation Oncology, Inc. - Bathi operasional sadurunge ngurangi amortisasi|Bathi operasional EBITDA iCAD, Inc. ICAD|Ikena Oncology, Inc. - Bathi operasional EBITDA|NTBL - Bathi operasional EBITDA|VIRX (Viracta Therapeutics) - Bathi operasional sadurunge ngurangi amortisasi|MorphoSys AG - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|NAYA (NAYA Biosciences Corp) - Bathi operasional EBITDA|Bathi operasional EBITDA Ascentage Pharma Group International
